Robert M. Conry
Publications by Year
Research Areas
Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma(2011)881 cited
- → Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group(2006)596 cited
- → Sorafenib for Advanced and Refractory Desmoid Tumors(2018)434 cited
- → Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134(2022)410 cited
- → Talimogene laherparepvec: First in class oncolytic virotherapy(2018)329 cited
- → Human Immune Respone to Monoclonal Antibodies(1994)297 cited
- → Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)(2011)210 cited
- → Smoldering myocarditis following immune checkpoint blockade(2017)202 cited
- → MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial(2018)193 cited
- → Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma(2018)175 cited